January 2024
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Nordisk, Ozempic, Constant – dosing instruction fragment, exchange rate
GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun
Arexvy, Respiratory syncytial virus, battle, begun
FDA rejects Defender’s motion sickness treatment
United States Food and Drug Administration, Safety, Effectiveness
Gilead Expands Arcus Collaboration with $320M Equity Investment
Investments, Arcus, Gilead, Combined, Phase 3 Clinical Trials
Promising Vertex Pain Med Points to New Era for Analgesics
historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects
Gene editing delivery biotech GenEdit partners with Genentech, raises another $24M
genentech, GenEdit, Gene Modification, Obstetric Delivery
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis, Dupixent, Child, Treatment intent, sanofi, Regeneron
Fake versions of Novo Nordisk’s Ozempic linked to 3 dangerous hypoglycemia cases in US: Reuters
Hypoglycemia, Case (situation), Ultrasonography, Nordisk’s, United States Food and Drug Administration
Lillys Investigational Gene Therapy Restores Hearing in First Treated Patient
Hearing, Treating, gene therapy, AK-OTOF